Summary: Alkermes plc is set to present data from its phase 1b study of ALKS 2680, a novel oral orexin 2 receptor agonist, at Sleep Europe 2024. The study evaluated ALKS 2680 in patients with narcolepsy type 2 and idiopathic hypersomnia, showing improved wakefulness compared to … [Read more...]
Phase 2 Study of ALKS 2680 Begins for Narcolepsy Type 2
Summary: Alkermes plc has initiated the Vibrance-2 study, a phase 2 clinical trial designed to evaluate the safety and efficacy of ALKS 2680, a novel oral orexin 2 receptor agonist, in treating narcolepsy type 2. The study will involve approximately 80 adults with narcolepsy type … [Read more...]
Alkermes Reports Q2 Advances in Narcolepsy Therapy With ALKS 2680 Results
Summary: Alkermes reported its Q2 2024 financial performance and advances in the development of narcolepsy treatments, particularly with the investigational drug ALKS 2680. The company highlighted its financial position, double-digit growth, and progress in its neuroscience … [Read more...]
Alkermes to Present Data for ALKS 2680 in Narcolepsy Treatment | Sleep Review
Summary: Alkermes plc introduced plans to present 3 posters at Rest 2024, showcasing the probable positive aspects of its investigational orexin 2 receptor agonist, ALKS 2680, for narcolepsy therapy. Displays will consist of information from a period 1b research, the layout of … [Read more...]
ALKS 2680 Improves Wakefulness in Narcolepsy Type 2 and IH
Summary: Alkermes plc introduced favourable benefits from a phase 1b research evaluating ALKS 2680, an oral orexin 2 receptor agonist, for dealing with narcolepsy variety 2 and idiopathic hypersomnia. The analyze showed statistically sizeable enhancements in wakefulness and rest … [Read more...]